Imiquimod

Imiquimod (CAS 99011-02-6) is an orally bioavailable imidazoquinoline compound that acts primarily as a Toll-like receptor 7 (TLR7) agonist in immune cells and exhibits immune response-modulating activity in other cell types. In addition, it modulates local cytokine production by activating innate immune pathways.

In experimental models, imiquimod induces the production of interferon-alpha and other immunomodulatory pro-inflammatory cytokines, an effect detectable by elevated cytokine levels in treated peripheral blood mononuclear cells (PBMCs) and skin explants. Imiquimod has been tested in various virus-infected cell lines and tumor cell models, showing that it enhances antiviral and anti-tumor immune responses by activating dendritic cells and subsequent T-cell priming. Imiquimod also stimulates the expression of interferon-stimulated genes and promotes interleukin release, thereby enhancing innate and adaptive immunity.

In pharmaceutical and biomedical research, imiquimod is widely used in the study of external genital and perianal warts, cancer immunotherapy, and investigation of virus infection-related immune responses (including COVID-19). In preclinical and clinical studies, imiquimod is used to investigate its mechanism of action as an immune response modulator and its application in therapeutic strategies for infectious and neoplastic diseases.

Topical application of imiquimod to the dorsal skin of mice induces psoriasis-like skin lesions and is commonly used to establish psoriasis animal models.